“Pfizer, BridgeBio, and Alnylam Battle It Out After Amvuttra’s Game-Changing Approval”
The FDA on Thursday approved Alnylam’s RNAi therapeutic a few days ahead of schedule, giving Amvuttra (vutrisiran) a green light to treat transthyretin-mediated amyloid cardiomyopathy […]